Prof. Hermann Einsele (University of Würzburg, Germany) discussed CAR-T therapy in the multiple myeloma (MM) treatment pathway . The take-home message of Prof. Einsele’s presentation was that CAR-T therapy be indicated in MM in the following three scenarios: (1) in patients who are not eligible for autologous transplant, CAR-T may consolidate or maintain remission; however, safety is a concern; (2) in patients who are eligible for autologous transplant there are 2 main groups who may benefit – those with adverse cytogenetics and those who progress early. In both populations, the long-term efficacy needs to be shown; and (3) heavily pre-treated patients (double-penta refractory) may also obtain some benefit, but the efficacy of CAR-T in this population must be shown with minimal residual disease (MRD)-negativity for prolonged PFS.
Patients with an MRD-negative state appear to have the same prognosis, regardless of whether they have standard or high-risk disease. However,...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Gilteritinib prolongs overall survival in patients with FLT3-mutated relapsed/refractory AML Next Article
Unmutated IGHV as predictive factor for venetoclax/obinutuzumab benefit in frontline CLL »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.